Invizyne Technologies (NASDAQ:IZTC) vs. Invivyd (NASDAQ:IVVD) Head to Head Analysis

Invizyne Technologies (NASDAQ:IZTC) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Profitability

This table compares Invizyne Technologies and Invivyd’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Invivyd	N/A	-155.33%	-114.88%

Valuation and Earnings

This table compares Invizyne Technologies and Invivyd”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Invivyd	$36.69 million	2.96	-$198.64 million	($1.20)	-0.75

Invizyne Technologies has higher earnings, but lower revenue than Invivyd.

Institutional and Insider Ownership

70.4% of Invivyd shares are owned by institutional investors. 25.4% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Invizyne Technologies and Invivyd, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0	0	0	0	0.00
Invivyd	0	0	3	1	3.25

Invivyd has a consensus target price of $5.85, suggesting a potential upside of 546.05%. Given Invivyd’s stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Invizyne Technologies.

Summary

Invivyd beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

About Invivyd

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.